Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
321.8 INR | -1.76% | -3.70% | -18.57% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With a 2024 P/E ratio at 27.21 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.57% | 362M | B- | ||
+32.95% | 709B | C+ | ||
+30.77% | 595B | B | ||
-1.89% | 367B | C+ | ||
+20.14% | 334B | B- | ||
+5.79% | 289B | C+ | ||
+14.77% | 239B | B+ | ||
+9.13% | 211B | B- | ||
-3.97% | 203B | A+ | ||
+8.95% | 171B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- INDOCO Stock
- Ratings Indoco Remedies Limited